Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment

Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent

(2011) Jing Yuan et al.   AIDS

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals

(2011) A. Schipani et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Chemokine (C-C Motif) Receptor 5 −2459 Genotype in Patients Receiving Highly Active Antiretroviral Therapy: Race-Specific Influence on Virologic Success

(2011) Rajeev K. Mehlotra et al.   JOURNAL OF INFECTIOUS DISEASES

Polymorphic Variants of Cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) Exhibit Altered Rates of Metabolism for Bupropion and Efavirenz: A Charge-Reversal Mutation in the K139E Variant (CYP2B6.8) Impairs Formation of a Functional Cytochrome P450-Reductase Complex

(2011) H. Zhang et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Transcriptional diversity at the UGT2B7 locus is dictated by extensive pre-mRNA splicing mechanisms that give rise to multiple mRNA splice variants

(2011) Vincent Ménard et al.   Pharmacogenetics and Genomics

Efavirenz Plasma Concentrations and Cytochrome 2B6 Polymorphisms

(2010) Tristan Lindfelt et al.   ANNALS OF PHARMACOTHERAPY

Genetic Variations in UDP-glucuronosyltransferase 2B7 Gene (UGT2B7) in a Korean Population

(2010) Mi-Sun Hwang et al.   Drug Metabolism and Pharmacokinetics

Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK

(2010) PJ Easterbrook et al.   HIV MEDICINE

Global patterns of genetic diversity and signals of natural selection for human ADME genes

(2010) Jing Li et al.   HUMAN MOLECULAR GENETICS

Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort

(2010) D. F. Carr et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Effect ofCYP2B6,ABCB1, andCYP3A5Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study

(2010) Heather J. Ribaudo et al.   JOURNAL OF INFECTIOUS DISEASES

Integrating common and rare genetic variation in diverse human populations

(2010)   NATURE

A map of human genome variation from population-scale sequencing

(2010) Richard M. Durbin et al.   NATURE

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients

(2010) Laure Elens et al.   PHARMACOGENOMICS

CYP2B6 Polymorphism and Nonnucleoside Reverse Transcriptase Inhibitor Plasma Concentrations in Chinese HIV-Infected Patients

(2010) Jun Chen et al.   THERAPEUTIC DRUG MONITORING

CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients

(2009) Awewura Kwara et al.   AIDS

Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients

(2009) S. E. Cabrera et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacogenetics of antiretrovirals

(2009) Valerio Tozzi   ANTIVIRAL RESEARCH

Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine

(2009) A.-S. Belanger et al.   DRUG METABOLISM AND DISPOSITION

Modulation of UDP-glucuronosyltransferase activity by protein-protein association

(2009) Yuji Ishii et al.   DRUG METABOLISM REVIEWS

Association of testicular germ cell tumor with polymorphisms in estrogen receptor and steroid metabolism genes

(2009) Alberto Ferlin et al.   ENDOCRINE-RELATED CANCER

Efavirenz in the therapy of HIV infection

(2009) Natella Y Rakhmanina et al.   Expert Opinion on Drug Metabolism & Toxicology

Cytochrome P450 2B6 516G→T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population

(2009) TW Mahungu et al.   HIV MEDICINE

Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine

(2009) G. Ramachandran et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Interindividual Variability in Pharmacokinetics of Generic Nucleoside Reverse Transcriptase Inhibitors in TB/HIV-Coinfected Ghanaian Patients:UGT2B7*1c Is Associated With Faster Zidovudine Clearance and Glucuronidation

(2009) Awewura Kwara et al.   JOURNAL OF CLINICAL PHARMACOLOGY

CYP2B6Variants and Plasma Efavirenz Concentrations during Antiretroviral Therapy in Port‐au‐Prince, Haiti

(2009) Paul Leger et al.   JOURNAL OF INFECTIOUS DISEASES

Associations betweenCYP2B6Polymorphisms and Pharmacokinetics after a Single Dose of Nevirapine or Efavirenz in African Americans

(2009) David W. Haas et al.   JOURNAL OF INFECTIOUS DISEASES

Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival

(2009) Mari M. Kitahata et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene

(2009) Federico Innocenti et al.   Pharmacogenetics and Genomics

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

(2009) Julia di Iulio et al.   Pharmacogenetics and Genomics

Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique

(2009) Cinzia Ciccacci et al.   PHARMACOGENOMICS

Pharmacokinetics of Plasma Efavirenz and CYP2B6 Polymorphism in Southern Chinese

(2009) Kin Wang To et al.   THERAPEUTIC DRUG MONITORING

Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?

(2008) Margalida Rotger et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

(2008) C. Wyen et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver

(2008) M. H. Hofmann et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Genome-Wide Analysis of Single Nucleotide Polymorphisms Uncovers Population Structure in Northern Europe

(2008) Elina Salmela et al.   PLoS One

Pharmacogenetics of Anti-HIV Drugs

(2007) A. Telenti et al.   Annual Review of Pharmacology and Toxicology